Clin2
NCT07762287Possibly a fitRecruiting

How two forms of elinzanetant are processed in healthy women

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women

This study looks at how the body handles two different forms of a drug called elinzanetant in healthy women. It helps doctors understand the drug's effects and may guide future treatment options.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
100 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • Be a woman aged 18 to 65
  • Be in good overall health
  • Weigh at least 50 kg (about 110 lbs) and have a BMI between 18 and 32
  • Agree to use effective birth control if you could become pregnant
  • Not have taken certain medications or participated in another trial recently

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07602530Recruiting
Tracking Hot Flash Treatment Outcomes in Canadian Women

This study follows women in Canada who are starting fezolinetant, a new medication for hot flashes during menopause. Researchers will track how well it works and how you feel while using it in your regular doctor's care.

Montreal
NCT07490431Not yet recruiting
Observational study of elinzanetant for menopause symptoms

This study looks at how women use a newer medicine called elinzanetant to manage hot flashes and night sweats from menopause. It's an observational study, meaning you'll continue your regular care while sharing how you're feeling through online surveys.

Whippany, New Jersey
NCT06116045Recruiting· Phase 2
Study of BZ371A for women with sexual arousal disorder

This trial tests an investigational medication, BZ371A, to see if it can help women with Female Sexual Arousal Disorder (FSAD), a condition where they have trouble getting or keeping physical signs of arousal like lubrication and warmth. The study aims to find out if BZ371A is safe, effective, and well-tolerated.

Rio de Janeiro, Rio de Janeiro
NCT07606664Not yet recruiting· Phase 3
Fezolinetant for Hot Flashes and Brain Health

This study tests whether fezolinetant, a new medication, can reduce moderate-to-severe hot flashes and night sweats during menopause while protecting heart and brain health. Participants will receive the study drug or placebo and have regular check-ups including brain imaging.

Chicago, Illinois
NCT07077395Recruiting· Phase 2
Hot flash study to check heart health links

This study looks at how hot flashes in midlife women might be connected to heart disease risk. Researchers want to see if managing hot flashes can improve heart health.

Boston, Massachusetts
NCT06995820Recruiting· Phase 1
Safety study of AZD1613 in healthy volunteers

This is a first-in-human trial testing an experimental drug (AZD1613) in healthy volunteers. It helps doctors see if the drug is safe, how it is processed by the body, and how the immune system reacts. The trial is designed for healthy men and women who cannot become pregnant and may require participants to be of Chinese or Japanese descent for certain groups.

Glendale, California

Hear when a new Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.